BUFFALO GROVE, Ill., June 1, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present a corporate overview at the 5th Annual LD Micro Invitational Conference in Los Angeles, CA, on Tuesday, June 2, 2015 at 4:30 pm PT.
About RestorGenex Corporation
RestorGenex is a specialty biopharmaceutical company focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the ophthalmologic, oncologic and dermatologic space. RestorGenex’s lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. The current pipeline also includes a “soft” anti-androgen compound for the treatment of acne vulgaris. RestorGenex’s novel inhibition of the PI3K pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating safe and effective treatments and innovative therapies. For additional information please see: www.restorgenex.com.
CONTACT: The Trout Group LLC Marcy Nanus, 646-378-2927 mnanus@troutgroup.com PCG Advisory Group Stephanie Prince, 646-762-4518 sprince@pcgadvisory.com
Help employers find you! Check out all the jobs and post your resume.
